Primary care and abortion provider perspectives on mail-order medication abortion: a qualitative study
Authors:
Open Access
- 3 July 2024
- journal article
- research article
- Published by Springer Nature in BMC Women's Health
- Vol. 24 (1) , 1-12
Abstract
Background: This qualitative study aims to assess perspectives of clinicians and clinic staff on mail-order pharmacy dispensing for medication abortion. Methods: Participants included clinicians and staff involved in implementing a mail-order dispensing model for medication abortion at eleven clinics in seven states as part of a prospective cohort study, which began in January 2020 (before the FDA removed the in-person dispensing requirement for mifepristone). From June 2021 to July 2022, we invited participants at the participating clinics, including six primary care and five abortion clinics, to complete a semi-structured video interview about their experiences. We then conducted qualitative thematic analysis of interview data, summarizing themes related to perceived benefits and concerns about the mail-order model, perceived patient interest, and potential barriers to larger-scale implementation. Results: We conducted 24 interviews in total with clinicians (13 physicians and one nurse practitioner) and clinic staff (n = 10). Participants highlighted perceived benefits of the mail-order model, including its potential to expand abortion services into primary care, increase patient autonomy and privacy, and to normalize abortion services. They also highlighted key logistical, clinical, and feasibility concerns about the mail-order model, and specific challenges related to integrating abortion into primary care. Conclusion: Clinicians and clinic staff working in primary care and abortion clinics were optimistic that mail-order dispensing of medication abortion can improve the ability of some providers to provide abortion and enable more patients to access services. The feasibility of mail-order pharmacy dispensing of medication abortion following the Supreme Court Dobbs decision is to be determined. Trial registration: Registry: Clinicaltrials.gov. Trial registration number: NCT03913104. Date of registration: first submitted on April 3, 2019 and first posted on April 12, 2019.Keywords
Funding Information
- Society of Family Planning
This publication has 25 references indexed in Scilit:
- Mail-Order Pharmacy Dispensing of Mifepristone for Medication Abortion After In-Person ScreeningJAMA Internal Medicine, 2024
- Outcomes and Safety of History-Based Screening for Medication AbortionJAMA Internal Medicine, 2022
- Mail-order pharmacy dispensing of mifepristone for medication abortion after in-person clinical assessmentContraception, 2022
- Exploring the impact of mifepristone's risk evaluation and mitigation strategy (REMS) on the integration of medication abortion into US family medicine primary care clinics✰,✰✰Contraception, 2022
- Family medicine provision of online medication abortion in three US states during COVID-19Contraception, 2021
- Society for Maternal-Fetal Medicine Special Statement: Maternal-fetal medicine subspecialist survey on abortion training and service provisionAmerican Journal of Obstetrics and Gynecology, 2021
- Obstetrician-gynecologist willingness to provide medication abortion with removal of the in-person dispensing requirement for mifepristoneContraception, 2021
- Expanding access to medication abortion through pharmacy dispensing of mifepristone: Primary care perspectives from IllinoisContraception, 2021
- Online access to abortion medications: a review of utilization and clinical outcomesBest Practice & Research Clinical Obstetrics & Gynaecology, 2020
- Support for and interest in alternative models of medication abortion provision among a national probability sample of U.S. womenContraception, 2019